Analyst Price Targets — BCRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 5, 2025 10:41 am | Jonathan Wolleben | JMP Securities | $25.00 | $6.97 | TheFly | BioCryst price target lowered to $25 from $27 at Citizens JMP |
| November 4, 2025 10:07 am | — | Barclays | $9.00 | $6.86 | TheFly | BioCryst price target lowered to $9 from $11 at Barclays |
| October 14, 2025 7:51 pm | — | RBC Capital | $15.00 | $6.42 | TheFly | BioCryst weakness presents 'compelling' buying opportunity, says RBC |
| October 14, 2025 7:21 pm | Maury Raycroft | Jefferies | $15.00 | $6.42 | TheFly | BioCryst price target raised to $15 from $14 at Jefferies |
| October 1, 2025 12:36 pm | — | Evercore ISI | $8.00 | $7.24 | TheFly | BioCryst downgraded to In Line from Outperform at Evercore ISI |
| August 6, 2024 5:31 am | Gena Wang | Barclays | $7.00 | $7.51 | TheFly | BioCryst price target raised to $7 from $6 at Barclays |
| August 5, 2024 4:01 pm | Maury Raycroft | Jefferies | $11.00 | $7.51 | StreetInsider | BioCryst Pharma (BCRX) PT Raised to $11 at Jefferies |
| November 2, 2022 6:28 am | Liisa Bayko | Evercore ISI | $16.00 | $12.39 | StreetInsider | UPDATE: Evercore ISI Upgrades BioCryst Pharma (BCRX) to Outperform |
| August 23, 2022 11:14 am | Gena Wang | Barclays | $14.00 | $14.33 | Pulse 2.0 | BioCryst (BCRX) Stock: $14 Target And Equal-Weight Rating |
| January 10, 2022 12:00 am | Ken Cacciatore | Cowen & Co. | $25.00 | $14.78 | StreetInsider | BioCryst Pharma (BCRX) PT Raised to $25 at Cowen on Orladeyo Sales Data |
Latest News for BCRX
RESEARCH TRIANGLE PARK, N.C., March 04, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the compensation committee of BioCryst's board of directors granted six newly-hired employees restricted stock units (RSUs) covering an aggregate of 65,850 shares of BioCryst common stock. The RSUs were granted as of March 2, 2026, as inducements material to each employee entering into…
Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the thirteen analysts that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating
BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2025 Earnings Call Transcript
BioCryst Pharmaceuticals (BCRX) came out with quarterly earnings of $1.12 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to a loss of $0.13 per share a year ago.
—Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the European ORLADEYO business to Neopharmed Gentili S.p.A. on October 1, 2025)—
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BCRX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.